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Objective: Gadolinium, a lanthanide cation, ameliorates pathophysiologic features
of both heart failure and cardiac arrhythmias. We have shown, in an in vitro model,
that gadolinium blocks stretch-induced contractile dysfunction in both normal and
stunned myocardium. The present study tested the hypothesis that gadolinium
would also attenuate regional myocardial stunning in an in vivo model.
Methods: Mongrel dogs (n  13) were subjected to regional myocardial ischemia
(occlusion of the left anterior descending coronary artery) for 15 minutes, followed
by reperfusion for 180 minutes. Intravenous gadolinium (500 mol) was given to 7
dogs before ischemia; no gadolinium was given to control animals. Regional
contractile function was assessed serially by means of both systolic shortening
(percentage) and regional preload recruitable stroke work.
Results: Administration of gadolinium before ischemia had no effect on heart rate,
arterial blood pressure, stroke volume, or regional contractile function. Ischemia
resulted in paradoxical systolic bulging in both groups. After 180 minutes of
reperfusion, systolic shortening was enhanced in gadolinium-treated animals com-
pared with that in control animals (10.9% 1.5% vs 2.4% 1.7%, P .003). Both
the slope and x-axis intercept of regional preload recruitable stroke work returned to
preischemic values in treated animals but remained abnormal in control animals.
Conclusions: These data confirm that gadolinium attenuates regional myocardial
stunning in vivo. Gadolinium may cause peripheral vasodilatation but does not
appear to exert positive inotropic effects on the normal canine heart. The mechanism
underlying gadolinium-mediated effects on stunned myocardium remains unde-
fined, but this study suggests that use of gadolinium may represent a novel adjunct
to current cardioprotective strategies.
Recent reports indicate that gadolinium, a trivalent lanthanide cation,exerts a number of interesting effects on myocardial pathophysiol-ogy. Stretch-induced arrhythmias in both rabbit atria and canineventricles are suppressed by gadolinium.1,2 Abnormal, swelling-induced ion currents that can be measured in cardiomyocytes fromdogs with tachycardia-induced heart failure are also inhibited by
gadolinium.3,4
Our laboratory has recently demonstrated, by using an isolated guinea pig
papillary muscle model, that stretch-induced contractile dysfunction is attenuated by
gadolinium both in normal myocardium and in myocardium that has been exposed
to modified hypoxia-reoxygenation.5 On the basis of these observations in an in
vitro model, we hypothesized that gadolinium would attenuate regional, postisch-
emic contractile dysfunction (stunning) in vivo as well. Myocardial stunning is a
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complex, probably multifactorial process that remains in-
completely understood. Observations made with an in vitro
model with a crystalloid perfusate may not correlate with
events that occur in association with ischemia and reperfu-
sion in vivo because blood elements, particularly neutro-
phils, may play a key role in the pathophysiology.6 Regional
stunning remains an important problem in cardiac opera-
tions, particularly in emergency procedures for acute coro-
nary syndromes. Adjunctive therapies that can accelerate
recovery of contractile function after reperfusion could have
an obvious clinical effect. Accordingly, the present study
tested the effects of intravenous gadolinium on serial meas-
ures of regional contractile function and hemodynamics in a
canine model of in vivo myocardial stunning.
Methods
Instrumentation
Mongrel dogs (n  13, approximately 25 kg) were anesthetized
with intravenous pentobarbital (200 mg/kg) and barbital (26 mg/
kg), intubated, and ventilated with supplemental oxygen. Normo-
thermia was maintained with heating blankets. Catheters were
placed into the femoral artery and vein. The heart was exposed by
means of a left thoracotomy, and the left anterior descending
coronary artery (LAD) was encircled with a silk thread immedi-
ately distal to the first diagonal branch. A micromanometer-tipped
catheter (Millar Instruments, Inc, Houston, Tex) was inserted into
the subclavian artery and was advanced retrograde across the
aortic valve into the left ventricle. Two cylindrical ultrasonic
dimension crystals (Triton Technology, Inc, San Diego, Calif)
were imbedded into the midmyocardium 1 cm apart in the distal
LAD territory and were connected to an ultrasonic dimension
system (Crystal Biotech, Hopkinton, Mass). An ultrasonic flow
probe (Transonics Systems, Inc, Ithaca, NY) was placed around
the pulmonary artery and connected to a flowmeter (model T101,
Transonics). The inferior vena cava was encircled with a reversible
snare. Animals were stabilized for at least 15 minutes. Hematocrit
and arterial blood gas levels were monitored throughout each
experiment. Supplemental barbiturate anesthesia was given as
indicated by corneal and hemodynamic reflexes.
Protocol
Heparin (100 U/kg) and lidocaine (30 mg) were administered
intravenously, and then baseline data were collected. Gadolinium
(500 mol administered intravenously) was then administered to
one group of animals (n  7) in an unblinded fashion, and another
data set was collected 5 minutes after injection in those animals.
Gadolinium chloride hexahydrate (Aldrich Chemical, Milwaukee,
Wis) was dissolved in 10 mL of 0.9% NaCl solution and injected
as a bolus. The LAD was then occluded in all animals by snaring
the silk suture. In gadolinium-treated animals the interval between
administration of gadolinium and the onset of ischemia was ap-
proximately 15 minutes. Additional lidocaine (100 mg) was given
to all animals as a continuous infusion during the occlusion.
Ventricular fibrillation was treated as necessary with direct-current
countershock. Data were collected after 10 minutes of ischemia.
The coronary snare was released after 15 minutes, and the isch-
emic segment was reperfused for 180 minutes. Final data were
collected after 180 minutes.
All animals were killed at the end of the protocol by inducing
ventricular fibrillation after achievement of deep general anesthe-
sia. All animals received humane care in compliance with the
“Principles of Laboratory Animal Care” formulated by the Na-
tional Society for Animal research and the “Guide for the Care and
Use of Laboratory Animals” prepared by the Institute of Labora-
tory Animal Resources, National Research Council, and published
by the National Academy Press, revised 1996. This study was
approved by the Medical College of Wisconsin Animal Care
Committee.
Data Analysis
Hemodynamic and regional dimension data were collected at
baseline, 5 minutes after injection of gadolinium (gadolinium-
treated animals), after 10 minutes of ischemia, and after 180
minutes of reperfusion. Data were digitized at 250 Hz per channel
and stored directly to computer disk by means of commercial
software (Codas, Akron, Ohio). Heart rate, mean arterial pressure,
and stroke volume were measured in triplicate during a steady state
and averaged. Right ventricular stroke volume was determined by
integrating pulmonary artery flow on a beat-to-beat basis and was
assumed to be equal to left ventricular stroke volume. The first
derivative of left ventricular pressure with respect to time (dP/dt)
was used to define events in the cardiac cycle.
Steady-state regional systolic shortening (in percentage) was
derived from dimension data and was defined by the following
formula:
SS  (EDL  ESL)/EDL
where SS is systolic shortening, EDL is end-diastolic length, and
ESL is end-systolic length. End-diastole was defined as the point
40 ms before peak positive dP/dt, and end-systole was defined as
the point 12 ms before peak negative dP/dt.
Instantaneous pressure-dimension relations were used to define
regional preload recruitable stroke work (rPRSW) relations, as
described by Glower and colleagues7 and as modified by the
authors.8-10 Raw data were analyzed by means of commercial
software (Mathcad 6.0 Standard Edition; Mathsoft Inc, Cambridge,
Mass). In brief, a family of pressure-dimension loops was gener-
ated while preload was varied during transient inferior vena caval
occlusion. Regional stroke work (SW; in millimeters of mercury
per millimeter) was defined as follows:
SW  LVP  d
where left ventricular pressure (LVP) is integrated over the period
from end-diastole to end-systole and d is defined as EDL minus
ESL. Stroke work was then plotted on a beat-to-beat basis as a
function of EDL and fitted to the following linear formula:
SW Mw (EDL  Dw)
The slope of the rPRSW relation (Mw; in millimeters of mercury)
varies directly with contractile state in a load-independent fashion.
The x-axis intercept of rPRSW (DW; in millimeters) represents the
theoretical segment length in the completely unloaded state. We10
have previously demonstrated that the value for Mw may lose
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correlation with contractile state during ischemia. In such circum-
stances Mw often retains a positive value, although all values for
SW during the inferior vena caval occlusion are negative because
of ischemic systolic paradox. When this occurs, the value for Mw
is disregarded.
Statistical Analysis
Statistical consultation was obtained from the Division of Biosta-
tistics of the Medical College of Wisconsin. Differences within the
gadolinium-treated group from baseline to before ischemia were
tested on each of 6 variables (Table 1) by means of a paired-
difference t test. A Bonferroni adjustment was used to control for
multiple testing, and statistical significance was defined as a P
value of less than .05/6 (.0083) for these tests. The Wilcoxon
signed-rank test was used to confirm these results and gave results
consistent with those of the t tests (data not shown).
Differences between groups were assessed by means of anal-
ysis of variance (ANOVA) for repeated measures before ischemia,
during ischemia, and during reperfusion. Separate analyses were
carried out for 3 hemodynamic variables (heart rate, mean arterial
pressure, and stroke volume) and for the 2 indices of contractile
function (systolic shortening and Dw) that could be measured at all
3 points in time. A Bonferroni adjustment was used to adjust the
statistical significance level within each group of variables to
control for multiple testing. In this manner statistical significance
is defined as a P value of less than .05/3 (.0167) for hemodynamic
variables and a P value of less than .05/2 (.025) for the indices of
contractile function. Time-by-group interaction was used to test for
different response profiles between the control and gadolinium-
treated groups. When this test result was significant, contrast tests
were conducted to determine whether the return to preischemia
values at reperfusion differed between groups. Because of the
small sample size, a nonparametric analysis was performed to
confirm the results of repeated-measures ANOVA. Analogous
Wilcoxon rank sum tests were used to confirm all contrast test
results. All nonparametric tests gave the same conclusions as
repeated-measures ANOVA contrasts and are not presented here.
Results
Hemodynamics and regional contractile function in control
animals at baseline and in gadolinium-treated animals both
at baseline and after administration of gadolinium are sum-
marized in Table 1. There were no baseline differences
between control and gadolinium-treated animals with re-
spect to any measured parameters. Administration of intra-
venous gadolinium was associated with a slight decrease in
mean arterial pressure that was not significant after adjust-
ment for multiple testing (P  .012). Because gadolinium
had no measured effects on normal cardiac function, base-
line data were considered as the preischemic data for both
groups in all further comparisons.
The effects of regional ischemia and reperfusion are
summarized in Table 2 (hemodynamics and rPRSW rela-
tions) and Figure 1 (regional systolic shortening). Occlusion
TABLE 1. Comparison of control animals (n  6) at baseline with gadolinium animals (n  7) before (baseline) and after







HR (beats/min) 118 8 128 10 124 12
MAP (mm Hg) 114 8 118 8 110 9
SV (mL) 21.4 2.6 19.1 1.9 20.6 1.7
Systolic shortening (%) 20.9 3.5 15.5 1.8 14.7 1.7
Mw (mm Hg) 20.1 5.2 17.7 1.5 17.6 3.4
Dw (mm) 9.5 1.3 9.4 0.7 9.5 0.9
GAD, Gadolinium-treated dogs; HR, heart rate; MAP, mean arterial pressure; SV, stroke volume.
TABLE 2. Effects of regional myocardial ischemia and reperfusion on hemodynamics and rPRSW relations in control (n 
6) and gadolinium-treated (n  7) dogs
Before ischemia Ischemia Reperfusion
Control GAD Control GAD Control GAD
HR (beats/min) 118 8 128 10 113 9 123 12 115 12 123 12
MAP (mm Hg) 114 8 118 8 107 8 112 9 117 10 109 10
SV (mL) 21.4 2.6 19.1 1.9 22.4 2.0 19.0 1.6 18.3 2.6 18.8 2.1
Mw (mm Hg) 20.1 5.2 17.7 1.5 NA NA NA 16.1 4.0
Dw (mm) 9.5 1.3 9.4 0.7 16.0 1.2* 14.6 1.2* 13.0 0.8* 9.3 1.0†
HR, Heart rate; MAP, mean arterial pressure; SV, stroke volume; NA, not applicable (see text for explanation).
*P  .01 versus before ischemia.
†P  .012 versus control.
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of the LAD did not alter hemodynamics but was associated
with an expected decrease in regional systolic function that
was characterized by paradoxical wall motion (negative
systolic shortening in Figure 1) and was equal in both
groups. The values obtained during ischemia for Mw were
disregarded in both groups because of the lack of physio-
logic correlation (see explanation in the “Methods” section)
and are labeled as not applicable in Table 2. An ischemia-
induced increase in Dw, indicating the development of dia-
stolic creep, was observed in both groups (P  .0001 for
both groups).
Systemic hemodynamics remained unchanged in both
groups after 180 minutes of reperfusion. Regional systolic
shortening, however, was enhanced in gadolinium-treated
animals compared with in control animals (10.9%  1.6%
vs 2.4%  1.7%, P  .0014). The recovery of systolic
shortening was thus 72%  7% in gadolinium-treated ani-
mals and only 12%  12% in controls. The Mw demon-
strated a persistent lack of physiologic correlation in control
animals at 180 minutes of reperfusion but became valid
again in gadolinium-treated animals, with a mean value that
did not differ from the preischemia value. The x-axis inter-
cept of the rPRSW relation also returned to its preischemic
value in gadolinium-treated animals, indicating the resolu-
tion of diastolic creep, but remained elevated in control
animals (P  .0096).
Discussion
The current study confirms our hypothesis that preischemic
treatment with gadolinium attenuates contractile dysfunc-
tion after regional myocardial ischemia and reperfusion in
vivo. Both systolic shortening and the Mw were enhanced
after 180 minutes of reperfusion in gadolinium-treated an-
imals compared with that in untreated control animals. The
differences in systolic shortening between control and gad-
olinium-treated groups at reperfusion (Figure 1) quantify
the effects of gadolinium. The changes in Mw (Table 2)
provide qualitative proof of the effects of gadolinium on
contractile function. Slope could not be evaluated in control
animals during reperfusion because of the persistent lack of
physiologic correlation in this index, yet gadolinium-treated
animals exhibited normal rPRSW relations after 180 min-
utes of reperfusion. These results correlate with our previ-
ous in vitro study, in which gadolinium was observed to
attenuate stretch-induced contractile dysfunction in both
normal and stunned guinea pig papillary muscles.5 In addi-
tion, however, the present study demonstrates that ischemia-
induced diastolic dysfunction, as defined by the Dw is also
reversed during reperfusion by gadolinium.
The underlying mechanism of gadolinium-related effects
in the current study is not clear and may be multifactorial.
Data from in vitro studies indicate that gadolinium acts as a
nonselective antagonist of stretch-activated ion channels
(SACs) in normal cardiac myocytes.11-13 The importance of
SACs in cardiac disease has been implied by recent studies
in which gadolinium alters the pathophysiology of both
heart failure and arrhythmias.1-4 Although a role for SACs
in postischemic contractile dysfunction (stunning) has not
yet been established, regional myocardial ischemia is asso-
ciated with abnormal tissue stretch, both in paradoxical
systolic bulging and in diastolic creep.14,15 Isolated cardio-
myocytes subjected to stretch exhibit increased intracellular
diastolic calcium,16,17 which may be a central pathophysio-
logic mechanism of ischemia and reperfusion.18-21 There-
fore, one may speculate that an SAC antagonist could block
stretch-induced calcium entry into myocytes exposed to
ischemia and reperfusion in vivo and thus attenuate con-
tractile dysfunction.
We10 have previously reported that postischemic left
ventricular decompression with a ventricular assist device
(VAD) also enhances recovery of contractile function in the
same canine model of regional stunning. It is tempting to
speculate that the mechanism underlying these VAD-medi-
ated effects also involves SACs. We demonstrated in that
study that not only was abnormal segment stretch elimi-
nated during full VAD flow, but both systolic and diastolic
segment lengths were decreased well below normal preisch-
emic lengths. The effects of the VAD on recovery of con-
tractile function could not be related to any changes in
regional myocardial blood flow. Perhaps closure of SACs
during left ventricular decompression eliminates any con-
tribution of ischemia-induced stretching to calcium over-
load. Further studies are needed to determine the relation-
ship of SACs and the effects of mechanical circulatory
support devices.
Figure 1. Mean  SEM systolic shortening in gadolinium-treated
(n  7; shaded bars) and untreated control (n  6; open bars)
dogs subjected to regional myocardial ischemia and reperfusion.
Gadolinium was dissolved in 10 mL of saline solution and in-
jected intravenously after collecting preischemic data. *P < .002
versus preischemia; †P  .01 versus control.
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Properties of gadolinium unrelated to SACs may also
contribute to its observed effects on regionally stunned
myocardium. In certain species and cell types, gadolinium
exerts inhibitory effects on voltage-gated (ie, nonmechano-
gated) calcium channels, particularly L-type Ca chan-
nels.22,23 Effects on non-SAC channels may thus contribute
to attenuation of calcium overload in postischemic cells.
Gadolinium also exhibits certain anti-inflammatory proper-
ties that were recently described by Kono and colleagues24
to protect against endotoxin in hepatectomized rats. Cellular
injury caused by local inflammation, with liberation of toxic
oxygen free radicals, is thought to be another important
pathophysiologic mechanism of ischemia and reperfu-
sion.25-28 An anti-inflammatory effect might therefore be an
important aspect of the gadolinium-mediated effects that
were observed in the present study.
There was no evidence in the present study that gado-
linium has any intrinsic inotropic properties in normal myo-
cardium because both systolic shortening and rPRSW rela-
tions remained unchanged after intravenous administration
of gadolinium. Gadolinium may exert a peripheral vasodi-
lator effect in normal dogs, as indicated by the slight de-
crease in mean arterial pressure that occurred when gado-
linium was administered in the baseline state. This effect,
however, was not statistically significant and was not asso-
ciated with changes in stroke volume or heart rate. There-
fore, the effects of gadolinium on stunned myocardium
cannot be understood on the basis of its effects on normal
myocardium. In addition, we did not observe an increase in
contractile force when normal guinea pig papillary muscles
were exposed to gadolinium.5 The salutary effects of gad-
olinium on contractile function may be related to improved
conduction of electrical impulses through stunned myocar-
dium, reduced need for electrical defibrillation, or both. As
noted above, gadolinium reduces myocardial vulnerability
to stretch-induced arrhythmias. Unfortunately, however, we
did not maintain an arrhythmia history during these exper-
iments and are therefore unable to determine the role that
anti-arrhythmic effects may have played in our results.
The effect of the present study on clinical practice re-
mains speculative. Ischemia and reperfusion, however, re-
mains an important problem in cardiac operations, particu-
larly in the setting of acute coronary syndromes. Adjuncts
that could accelerate recovery of contractile function in
these patients would have obvious value. Gadolinium is
currently used clinically only as a contrast agent in magnetic
resonance imaging. The incidence of human toxicity of
gadolinium when used as a contrast agent is extremely low
(1%), and the majority of adverse reactions are allergic.
Nonallergic reactions include nausea and headache.29,30
These preliminary data with gadolinium support a rationale
to pursue further investigation into its mechanism or mech-
anisms of effect and possible applications. In particular,
gadolinium-mediated effects must be preserved if it is ad-
ministered during ischemia or on reperfusion to be useful
clinically. These temporal relationships can be determined
in future experiments.
In summary, pretreatment with gadolinium, an antago-
nist of SACs, accelerates recovery of contractile function
after regional myocardial ischemia and reperfusion in dogs.
Although the precise mechanism underlying this effect re-
mains unknown, gadolinium may represent a novel adjunct
in cardioprotective strategies.
We thank Mr Daniel Eastwood, Division of Biostatistics, for
his assistance with manuscript preparation.
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